focus -WSS

focus

author：entertainment 2025-10-02 04:55:33 - browse：878

Sanofi CEO Paul Hudson Courtesy Sanofi

NEW YORK — The top executives at French drug giant Sanofi on Wednesday defended their decision to reduce earnings forecasts for 2024 in order to fund more research studies of new medicines they say could one day generate billions of dollars in annual sales.

CEO Paul Hudson and Houman Ashrafian, Sanofi’s new head of R&D, made their remarks in an exclusive interview with STAT ahead of a full-day meeting with analysts here. When the cuts to earnings were first announced Oct. 27, along with a plan to spin off the company’s consumer products division, shares dove 18% and have yet to fully recover. The share price is down 5% since the beginning of 2023.

“I’ve been waiting four years for a situation where we could put [out] the pipeline, as impressive as it is, and declare that we’re going to be the world’s leading immunology company,” said Hudson, who took over as CEO in 2019. “So it’s quite an important moment for us. And it’s an important moment to declare that we’re back in science, because I could argue that we haven’t been where we needed to be.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： Wegovy, Zepbound and weight loss drugs that preserve muscle

WSS

The woman behind the Dana Farber

Ransomware attacks on hospitals: Study outlines patient impact

Readout Newsletter: The latest at Gilead, Catalent, and the NIH

Poor hospice wound care hurts patients and families

Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

David Sabatini, ex

entertainment

focus

entertainment

After affirmative action ruling, medical educators look to 'holistic review'

Teach medical students about patients with intellectual disabilities

Apple is now the first public company to be valued at $3 trillion

SCOTUS to consider access to abortion pill mifepristone

Novavax promises a turnaround & Lilly roils the obesity market

SCOTUS to consider access to abortion pill mifepristone

Sports medicine is finally prioritizing gender equality

A daunting task: navigating dual Medicare, Medicaid eligibility

What does generative AI mean for health care? We asked experts

World's first CRISPR

explore

Buoyed by wins on obesity, Novo Nordisk eyes heart disease

NYU radiologists take on the challenge of expensive MRI machines

Patients' immediate access to test results puts radiologists in a bind

Roche to buy Carmot Therapeutics, developer of obesity drugs

CMS should re

Morphosys mixed study results for blood cancer drug

hotspot

entertainment

focus

leisure time